Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04203342
Other study ID # 71864602
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date December 11, 2019
Est. completion date July 13, 2020

Study information

Verified date December 2019
Source Douglas Pharmaceuticals America Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis.


Description:

A randomized, double-blind, vehicle-controlled, parallel-design, multiple-site study to evaluate the clinical (therapeutic) effet of a generic Ketoconazole Cream 2% (Douglas Pharmaceuticals America Ltd) compared with the reference standard Ketoconazole Cream 2% (Teva Pharmaceuticals USA Inc) in subjects with a microbiologically-confirmed, clinical diagnosis of tinea pedis. Approximately 675 subjects, male or female, 18 years or older, will be enrolled.


Recruitment information / eligibility

Status Completed
Enrollment 682
Est. completion date July 13, 2020
Est. primary completion date May 28, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Healthy male or non-pregnant, non-lactating female, 18 years of age or older

- Signed ICF meeting all criteria of current FDA regulations

- Female subject of childbearing potential must NOT be pregnant or lactating at Visit 1 (negative urine pregnancy test)

- Female subject of childbearing potential must agree to use of reliable method of contraception.

- Clinical diagnosis of tinea pedis predominantly in interdigital spaces

- Tinea pedis confirmed at baseline by positive KOH wet mount.

- Sum of clinical signs and symptoms score of target lesion at least 4; in addition target lesion must have a minimum score of at least 2 for erythema and a minimum score of at least 2 for either pruritis or scaling.

Exclusion Criteria:

- Females who are pregnant, lactating or planning to become pregnant during the study period.

- history of, or current psoriasis, lichen planus, or contact dermatitis involving the feet within the previous 12 months.

- history of dermatophyte infections with a lack of response to antifungal systemic or topical therapy (recurrent tinea pedis [i.e.more than 3 infections in the past 12 months] that were unresponsive to previous antifungal therapy).

- history of allergy, hypersensitivity, or intolerance to ketoconazole, other imidazoles, sulfites or any other component of the study product.

- confluent, diffuse moccasin-type tinea pedis of the entire plantar surface.

- current uncontrolled diabetes.

- presence of any other infection of the foot or other disease process that, in the Investigator's opinion, may interfere with the evaluation of the subject's tinea pedis.

- known history of or current impaired wound healing, presence of peripheral vascular disease and/or trophic changes of the lower limbs to an extent that, in the opinion of the Investigator would make the subject unsuitable for the study or compromise subject's safety.

- Signficant history or current evidence of chronic infectious disease, system disorder, organ disorder, immunosuppression (due to disease or therapy, including history of organ transplant), or other medical condition that, in the opinion of the Investigator, would place the subject at undue risk by participating or compromise the integrity of the study data.

- Use of antipruritics, including antihistamines, within 72 hours prior to Visit 1.

- Use of topical corticosteroids, topical antibiotics or topical antifungal therapy (e.g. clotrimazole, econazole, fluconazole) within 2 weeks before Visit 1.

- Use of systemic (e.g. oral or injectable) antibiotics, systemic antifungal therapy, or systemic corticosteroids within 30 days before Visit 1. The use of intranasal, inhaled or ophthalmic corticosteroids for acute or chronic conditions (e.g. allergic conjunctivitis, asthma/COPD maintenance) is acceptable to the extent that, in the opinion of the Investigator, does not compromise safety of subject or integrity of the data.

- Use of oral terbinafine or itraconazole within 2 months before Visit 1.

- Use of immunosuppressive medication or radiation therapy within 3 months before Visit 1.

- Receipt of any drug as part of a research study within 30 days before Visit 1.

- Previous participation in this study.

- Employee of the Investigator or research centre or their immediate family members.

- Inability to understand the requirements of the study and the relative information or are unable or unwilling to comply with the study protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)
Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)
Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
Topical placebo to treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.

Locations

Country Name City State
Belize FXM Research International Belize City
United States Moore Clinical Research Brandon Florida
United States Moore Clinical Reseach Tampa Florida

Sponsors (3)

Lead Sponsor Collaborator
Douglas Pharmaceuticals America Ltd ACM Global Laboratories, Novum Pharmaceutical Research Services

Countries where clinical trial is conducted

United States,  Belize, 

Outcome

Type Measure Description Time frame Safety issue
Primary Therapeutic cure of tinea pedis The proportion of subjects in each treatment group with a Therapeutic Cure of tinea pedis at the test-of-cure visit conducted 2 weeks after the end of treatment (Day 56 +/- 4). Therapeutic cure is defined as having both a clinical and mycological cure of tinea pedis. 2 weeks post-treatment (Day 56)
Secondary Clinical cure of tinea pedis The proportion of subjects in each treatment group with a Clinical Cure at Day 56 +/- 4. Clinical Cure is defined as a total severity score of 0=none (complete absence of any sign or symptom)
Mild (slight)
moderate (definitely present)
Severe (Marked, intense).
The following signs and symptoms will be rated:
Signs = fissuring/cracking, erythema, maceration, and scaling Symptoms = pruritis and burning/stinging
2 weeks post-treatment (Day 56)
Secondary Mycological cure of tinea pedis The proportion of subjects in each treatment group with a Mycological Cure of tinea pedis at Day 56 +/- 4. Mycological Cure is defined as having a negative KOH test AND a negative fungal culture. 2 weeks post-treatment (Day 56)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05493488 - A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis Phase 2
Completed NCT04883593 - A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis. Early Phase 1
Terminated NCT02842021 - Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis Phase 2
Completed NCT01712360 - Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis Phase 4
Completed NCT00781664 - Cumulative Irritation Test Phase 1
Completed NCT03676686 - Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis N/A
Completed NCT01519752 - A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis Phase 1
Completed NCT03320486 - Non-inferiority Trial of Dapaconazole Versus Ketoconazole Phase 3
Completed NCT01580891 - Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis Phase 1
Completed NCT01353976 - Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis Phase 3
Completed NCT01349998 - Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis Phase 3
Completed NCT04265521 - Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet N/A
Completed NCT02633813 - BE Study of Naftifine HCL Phase 3
Recruiting NCT00856596 - Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females Phase 3
Completed NCT00869336 - Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot) Phase 2
Completed NCT00768599 - A Study of Econazole Foam 1% in Athlete's Foot Phase 2
Recruiting NCT00233493 - Spread of Dermatophytes Among Families N/A
Completed NCT03897257 - A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis Phase 2
Completed NCT03129321 - Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis Phase 3
Completed NCT02335255 - Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis Phase 1